Citigroup Inc Sarepta Therapeutics, Inc. Call Options Transaction History

Citigroup Inc

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 12, 2024	SELL	$124.33 - $156.75 $348,124 - $438,900	-2,800 Reduced 10.49%	23,900 $2.99 Million
Q2 2024 Aug 12, 2024	BUY	$113.33 - $163.85 $2.83 Million - $4.1 Million	25,000 Added 1470.59%	26,700 $4.22 Million
Q1 2024 May 10, 2024	SELL	$93.7 - $141.53 $1.25 Million - $1.88 Million	-13,300 Reduced 88.67%	1,700 $220,000
Q4 2023 Feb 09, 2024	SELL	$67.31 - $124.76 $336,550 - $623,800	-5,000 Reduced 25.0%	15,000 $1.45 Million
Q3 2023 Nov 09, 2023	BUY	$102.5 - $123.59 $2.05 Million - $2.47 Million	20,000 New	20,000 $2.42 Million
Q1 2023 May 11, 2023	BUY	$117.53 - $155.99 $2.5 Million - $3.32 Million	21,300 Added 21300.0%	21,400 $2.95 Million
Q4 2022 Feb 09, 2023	SELL	$100.86 - $132.13 $5.91 Million - $7.74 Million	-58,600 Reduced 99.83%	100 $12,000
Q3 2022 Nov 10, 2022	BUY	$75.71 - $119.24 $4.44 Million - $7 Million	58,700 New	58,700 $6.49 Million

530

84.5M

2.06M

1.52M

Ticker SRPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,567,904
Market Cap $12.1B
Description
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.